Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis

References

• Muchtar E, Dispenzieri A, Magen H, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021;289:268–292. doi:10.1111/joim.13169
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.
   PubMed Web of Science ®Google Scholar
• Fotiou D, Dimopoulos MA, Kastritis E. Systemic AL amyloidosis: current approaches to diagnosis and management. Hemasphere. 2020;4:e454. doi:10.1097/HS9.0000000000000454
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26:2317–2325. doi:10.1038/leu.2012.100
   PubMed Web of Science ®Google Scholar
• Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4:38. doi:10.1038/s41572-018-0034-3
   PubMed Web of Science ®Google Scholar
• Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Adv Ther. 2015;32:920–928. doi:10.1007/s12325-015-0250-0
   PubMed Web of Science ®Google Scholar
• Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016;128:159–168. doi:10.1182/blood-2016-01-629790
   PubMed Web of Science ®Google Scholar
• Chaulagain CP, Comenzo RL. New insights and modern treatment of AL amyloidosis. Curr Hematol Malig Rep. 2013;8:291–298. doi:10.1007/s11899-013-0175-0
   PubMed Web of Science ®Google Scholar
• Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126:612–615. doi:10.1182/blood-2015-01-620302
   PubMed Web of Science ®Google Scholar
• Dittrich T, Kimmich C, Hegenbart U, et al. Prognosis and staging of AL amyloidosis. Acta Haematol. 2020;143:388–400. doi:10.1159/000508287
   PubMed Web of Science ®Google Scholar
• Lin HM, Seldin D, Hui AM, et al. The patient’s perspective on the symptom and everyday life impact of AL amyloidosis. Amyloid. 2015;22:244–251. doi:10.3109/13506129.2015.1102131
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121:3420–3427. doi:10.1182/blood-2012-12-473066
   PubMed Web of Science ®Google Scholar
• Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020;95:848–860. doi:10.1002/ajh.25819
   PubMed Web of Science ®Google Scholar
• Sarosiek S, Zheng L, Sloan JM, et al. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. Blood Cancer J. 2020;10:88. doi:10.1038/s41408-020-00354-7
   PubMed Web of Science ®Google Scholar
• Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083–1093. doi:10.1056/NEJMoa070484
   PubMed Web of Science ®Google Scholar
• D'Souza A, Huang J, Hari P. New light chain amyloid response criteria help risk stratification of patients by day 100 after autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22:768–770. doi:10.1016/j.bbmt.2015.12.021
   PubMed Web of Science ®Google Scholar
• Minnema MC, Nasserinejad K, Hazenberg B, et al. Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica. 2019;104:2274–2282. doi:10.3324/haematol.2018.213900
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Sun F, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood. 2015;126:2345–2347. doi:10.1182/blood-2015-08-662726
   PubMed Web of Science ®Google Scholar
• Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385:46–58. doi:10.1056/NEJMoa2028631
   PubMed Web of Science ®Google Scholar
• Kastritis E, Roussou M, Gavriatopoulou M, et al. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015;90:E60–E65. doi:10.1002/ajh.23936
   PubMed Web of Science ®Google Scholar
• Nguyen VP, Landau H, Quillen K, et al. Modified high-dose melphalan and autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Biol Blood Marrow Transplant. 2018;24:1823–1827. doi:10.1016/j.bbmt.2018.06.018
   PubMed Web of Science ®Google Scholar
• Kastritis E, Fotiou D, Theodorakakou F, et al. Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. Amyloid. 2021;28:3–11. doi:10.1080/13506129.2020.1798224
   PubMed Web of Science ®Google Scholar
• Cibeira MT, Oriol A, Lahuerta JJ, et al. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Br J Haematol. 2015;170:804–813. doi:10.1111/bjh.13500
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Skinner M, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110:3561–3563. doi:10.1182/blood-2007-07-099481
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica. 2007;92:1415–1418. doi:10.3324/haematol.11413
   PubMed Web of Science ®Google Scholar
• Lee C, Lam A, Kangappaden T, et al. Systematic literature review of evidence in amyloid light-chain amyloidosis. J Comp Eff Res. 2022;11:451–472. doi:10.2217/cer-2021-0261
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. (2015). Single technology appraisal: user guide for company evidence submission template [cited 2021 Dec 14]. Available from: https://www.nice.org.uk/process/pmg24/chapter/clinical-effectiveness#quality-assessment-of-the-relevant-clinical-effectiveness-evidence.
   Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [cited 2021 Dec 14]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. doi:10.1186/1471-2288-12-9
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558. doi:10.1002/sim.1186
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315:629–634. doi:10.1136/bmj.315.7109.629
   PubMed Web of Science ®Google Scholar
• Sterne JA, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Br Med J. 2011;343:d4002. doi:10.1136/bmj.d4002
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–4549. doi:10.1200/JCO.2011.37.7614
   PubMed Web of Science ®Google Scholar
• Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014;99:1479–1485. doi:10.3324/haematol.2014.104109
   PubMed Web of Science ®Google Scholar
• Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica. 2014;99:743–750. doi:10.3324/haematol.2013.095463
   PubMed Web of Science ®Google Scholar
• Gatt ME, Hardan I, Chubar E, et al. Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment. Eur J Haematol. 2016;96:136–143. doi:10.1111/ejh.12558
   PubMed Web of Science ®Google Scholar
• Ravichandran S, Cohen OC, Law S, et al. Impact of early response on outcomes in AL amyloidosis following treatment with frontline bortezomib. Blood Cancer J. 2021;11:118. doi:10.1038/s41408-021-00510-7
   PubMed Web of Science ®Google Scholar
• Manwani R, Foard D, Mahmood S, et al. Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis. Haematologica. 2018;103:e165–e168. doi:10.3324/haematol.2017.178095
   PubMed Web of Science ®Google Scholar
• Roccatello D, Fenoglio R, Sciascia S, et al. CD38 and anti-CD38 monoclonal antibodies in AL amyloidosis: targeting plasma cells and beyond. Int J Mol Sci. 2020;21:4129. doi:10.3390/ijms21114129
   PubMed Web of Science ®Google Scholar
• Gatt ME. Light chain amyloidosis 2014. Int J Hematol. 2014;1:21–29. doi:10.12691/ijhd-1-1A-4.
   Google Scholar
• Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86:12–18. doi:10.4065/mcp.2010.0480
   PubMed Web of Science ®Google Scholar
• Palladini G, Schönland S, Merlini G, et al. First glimpse on real-world efficacy outcomes for 2000 patients with systemic light chain amyloidosis in Europe: a retrospective observational multicenter study by the European Myeloma Network. Blood. 2020;136:50–51. doi:10.1182/blood-2020-140708
   PubMed Web of Science ®Google Scholar
• Palladini G, Schönland S, Merlini G, et al. Systemic light chain amyloidosis across Europe: key outcomes from a retrospective study of 4500 patients. Blood. 2021;138:153. doi:10.1182/blood-2021-152675
   Web of Science ®Google Scholar
• Comenzo R, Kastritis E, Palladini G, et al. Reduction in absolute involved free light chain and difference between involved and uninvolved free light chain is associated with prolonged major organ deterioration progression-free survival in patients with newly diagnosed AL amyloidosis receiving bortezomib, cyclophosphamide, and dexamethasone with or without daratumumab: results from ANDROMEDA. Blood. 2020;136:48–50. doi:10.1182/blood-2020-137582
   Web of Science ®Google Scholar